Breaking News Instant updates and real-time market news.

TEVA

Teva

$11.85

0.02 (0.17%)

, JCP

J.C. Penney

$2.75

0.24 (9.56%)

07:35
11/10/17
11/10
07:35
11/10/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Teva (TEVA), J C Penney (JCP), Coca Cola (KO), Juniper (JNPR), Ensco (ESV), Avis Budget (CAR), Emerson (EMR), Cameco (CCJ), AmTrust (AFSI), and Quest Diagnostics (DGX).

TEVA

Teva

$11.85

0.02 (0.17%)

JCP

J.C. Penney

$2.75

0.24 (9.56%)

KO

Coca-Cola

$46.23

0.05 (0.11%)

JNPR

Juniper

$25.35

0.56 (2.26%)

ESV

Ensco

$6.17

0.25 (4.22%)

CAR

Avis Budget

$33.90

-1.425 (-4.03%)

EMR

Emerson

$61.48

-1.04 (-1.66%)

CCJ

Cameco

$9.34

0.32 (3.55%)

AFSI

AmTrust

$10.90

-1.36 (-11.09%)

DGX

Quest Diagnostics

$93.02

-0.13 (-0.14%)

  • 10

    Nov

  • 13

    Nov

  • 14

    Nov

  • 16

    Nov

  • 16

    Nov

  • 30

    Nov

  • 12

    Dec

TEVA Teva
$11.85

0.02 (0.17%)

11/07/17
11/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Neutral from Buy at Guggenheim. 2. Exxon Mobil (XOM) downgraded to Reduce from Hold at HSBC with analyst Gordon Gray saying he compares Exxon's valuation to Buy rated Shell's (RDS.A) saying it is a third higher, yet Shell generated $7B more underlying cash flow in the past 12 months, and he thinks Exxon's capex will rise by much more in 2018 in comparison. 3. Teva (TEVA) downgraded to Reduce from Hold at HSBC with analyst Steve McGarry saying the balance sheet is "over-stretched." 4. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Drexel Hamilton with analyst Bob Christensen citing the temporary stay issued on the Atlantic Sunrise pipeline. 5. SMIC (SMI) downgraded to Underperform from Neutral at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/17
HSBC
11/07/17
DOWNGRADE
Target $6
HSBC
Reduce
Teva downgraded to Reduce from Hold at HSBC
HSBC analyst Steve McGarry downgraded Teva to Reduce and slashed his price target on shares to $6 from $26. The analyst reduced estimates to reflect margin compression and lack of earnings growth and said the balance sheet is "over-stretched." McGarry said equity holders now have a risky investment and any rights issue to de-leverage the balance sheet will dilute equity investors, and bondholders could insist on a debt-for-equity swap, which would also be painful.
11/06/17
FBCO
11/06/17
NO CHANGE
Target $8
FBCO
Underperform
Teva price target lowered to $8 from $14 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Teva to $8 from $14 following Q3 results and yet another guidance reduction. The analyst reiterates an Underperform rating on the shares.
11/03/17
WELS
11/03/17
NO CHANGE
Target $12
WELS
Market Perform
Teva price target lowered to $12 from $17 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Teva Pharmaceutical to $12 saying the company's Q3 results and Q4 outlook were "especially disappointing." The revised his already below consensus numbers even lower and keeps a Market Perform rating on the name. He believes Teva's asset sales and debt restructuring will primarily benefit the debt holders, and as such, "equity holders will have to see what is left after the asset sales."
JCP J.C. Penney
$2.75

0.24 (9.56%)

10/30/17
SBSH
10/30/17
DOWNGRADE
Target $16
SBSH
Sell
Macy's downgraded to Sell from Neutral at Citi
Citi analyst Paul Lejuez downgraded Macy's (M) to Sell and cut his price target for the shares to $16 from $21. The retailer's sales and margins have been pressured for several years, and J.C. Penney's (JCP) weak Q3 preannouncement on Friday serves as reminder of just how challenging the department store space is, Lejuez tells investors in a research note. He believes risks are mounting at Macy's ahead of what is likely to be another promotional holiday season. Macy's has not found the right tools to offset negative store traffic and margin pressures, the analyst contends. Lejuez this morning also downgraded Penny to Sell.
10/30/17
SUSQ
10/30/17
DOWNGRADE
Target $3
SUSQ
Neutral
J.C. Penney downgraded to Neutral at Susquehanna
As reported previously, Susquehanna analyst Bill Dreher downgraded J.C. Penney to Neutral from Positive following its Q3 results. The analyst cited its continued gross margin pressures and the fact that sales driving initiatives are taking longer than expected to materialize. Dreher lowered his price target to $3 from $6.50 on J.C. Penney shares.
10/30/17
NRCS
10/30/17
DOWNGRADE
NRCS
Neutral
J.C. Penney downgraded to Neutral from Buy at Northcoast
10/30/17
10/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Motors (GM) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying his price target of $32 offers 28% potential downside. The analyst continues to believe the North America auto cycle has peaked and he remains cautious on the sector. 2. Merck (MRK) downgraded to Hold from Buy at SunTrust and to Equal Weight from Overweight at Morgan Stanley, as well as Barclays. 3. J.C. Penney (JCP) downgraded to Sell from Neutral at Citi, to Neutral from Buy at Northcoast, and to Neutral from Positive at Susquehanna. 4. Macy's (M) downgraded to Sell from Neutral at Citi with analyst Paul Lejuez saying the retailer's sales and margins have been pressured for several years, and J.C. Penney's weak third quarter preannouncement on Friday serves as reminder of just how challenging the department store space is. 5. Under Armour (UAA, UA) downgraded to Underperform from Neutral at BofA/Merrill with analyst Robert Ohmes saying he expects management to lower fourth quarter guidance on its Q3 conference call due to the highly promotional environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
KO Coca-Cola
$46.23

0.05 (0.11%)

06/07/17
BMOC
06/07/17
DOWNGRADE
BMOC
Market Perform
Coca-Cola downgraded on valuation at BMO Capital
As noted earlier, BMO Capital downgraded Coca-Cola to Market Perform from Outperform. Analyst Amit Sharma downgraded the stock based on valuation. Target remains $46.
06/07/17
06/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) and Coca-Cola (KO) were downgraded to Market Perform from Outperform at BMO Capital. 2. Rent-A-Center (RCII) downgraded to Sell from Hold at Loop Capital with analyst Anthony Chukumba saying the secular shift to "virtual" rent-to-own has impaired the value of the company's core U.S. business. 3. HD Supply (HDS) was downgraded to Neutral from Outperform at Baird and to Hold from Buy at Drexel Hamilton. 4. IMAX (IMAX) downgraded to Hold from Buy at Benchmark with analyst Mike Hickey saying he fears movie goers' enthusiasm for recliner installations has shifted share away from IMAX and he now worries that recent per screen average deterioration could "prove less than transitory." 5. Danaher (DHR) downgraded to Neutral from Buy at Janney Capital with analyst Paul Knight saying he sees the company having more work to do optimizing its portfolio. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
BMOC
09/08/17
NO CHANGE
BMOC
Coca-Cola unlikely to be crippled by Amazon, says BMO Capital
BMO Capital says that sales of Coca-Cola's (KO) core products probably won't drop significantly due to competition from private labels. These Coca-Cola products "have high brand equity and low private-label penetration," BMO explained. Moreover, the soft drink maker could actually benefit from increased sales of higher margin, smaller size products through Amazon (AMZN), the firm believes.
06/07/17
BMOC
06/07/17
DOWNGRADE
BMOC
Market Perform
Coca-Cola downgraded to Market Perform from Outperform at BMO Capital
JNPR Juniper
$25.35

0.56 (2.26%)

10/25/17
BMOC
10/25/17
NO CHANGE
Target $29
BMOC
Outperform
Juniper price target lowered to $29 from $31 at BMO Capital
BMO Capital analyst Tim Long lowered his price target on Juniper to $29 following "weak" Q3 results. Long says the timeline for recovery seems uncertain, adding that it may take several quarters to determine whether there has been any competitive displacement within its largest cloud customers. The analyst keeps his Outperform rating given Juniper's strong cash flow generation and opportunities for margin improvement.
10/12/17
MKMP
10/12/17
NO CHANGE
Target $29
MKMP
Neutral
Juniper price target lowered to $29 from $31 at MKM Partners
MKM Partners analyst Michael Genovese lowered his price target on Juniper Networks (JNPR) to $29 and kept his Neutral rating on the shares, saying that yesterday's Q3 cloud revenue miss reflects completion of large projects and also demonstrates heightened competition from companies like Arista (ANET), which he expects to beat its earnings consensus. Genovese also notes other challenges for Juniper, such as virtualization of routers and reliance on expensive proprietary silicon.
10/12/17
BMOC
10/12/17
NO CHANGE
Target $31
BMOC
Outperform
Juniper Q3 revenue miss not a sign of less traction in cloud, says BMO Capital
BMO Capital analyst Tim Long lowered his price target on Juniper Networks to $31 from $34 following yesterday's weaker than expected Q3 pre-announcement. Long attributes the miss to declining revenue in the cloud vertical after a 29% growth in that space during the first half. However, the analyst contends that the cloud business has "inherent lumpiness" and the Q3 announcement is not indicative of the company's diminishing traction, maintaining an Outperform rating on the stock.
10/13/17
OTRG
10/13/17
DOWNGRADE
OTRG
Mixed
Juniper downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Juniper following channel sources in Europe that suggest sales are below target due to Brexit and an overall sales slowdown.
ESV Ensco
$6.17

0.25 (4.22%)

09/25/17
UBSW
09/25/17
UPGRADE
Target $8
UBSW
Buy
Ensco upgraded to Buy from Neutral at UBS
UBS analyst Angie Sedita upgraded Ensco and other offshore drillers to Buy citing "early signs of a slow recovery." The analyst believes a bottom has been reached in offshore utilization for both floaters and jackups and that demand will slowly move higher in 2018. She views current valuations in the space as compelling and raised her price target for Ensco shares to $8 from $6.
10/10/17
DBAB
10/10/17
INITIATION
Target $6
DBAB
Hold
Ensco initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Havens started Ensco with a Hold rating and $6 price target.
10/13/17
GSCO
10/13/17
INITIATION
Target $8
GSCO
Buy
Ensco initiated with a Buy at Goldman Sachs
Goldman analyst Waqar Syed reinstated Ensco with a Buy and $8 price target following the merger with Atwood. The analyst views valuation as attractive and views it as a best in class offshore driller with low-risk exposure to an inflection in activity.
10/19/17
HSBC
10/19/17
INITIATION
Target $7.3
HSBC
Buy
Ensco initiated with a Buy at HSBC
HSBC analyst David Phillips started Ensco with a Buy rating and $7.30 price target. The analyst believes the Atwood deal gives the company's the largest fleet versus peers. He thinks Ensco's current low utilization rate is an opportunity and sees good valuation upside.
CAR Avis Budget
$33.90

-1.425 (-4.03%)

10/02/17
SUSQ
10/02/17
NO CHANGE
SUSQ
NADA data show slight improvement in September used car prices, says Susquehanna
Susquehanna said that data from NADA showed that seasonally adjusted used car prices declined 4.1% year-over-year and increased 1.2% month-over-month in September. While the firm expects recent hurricanes to be a near-term benefit to used car prices, it thinks any near-term improvement will be short-lived. Hertz (HTZ) and Avis Budget (CAR) are near-session highs in afternoon trading.
10/12/17
MKMP
10/12/17
NO CHANGE
Target $49
MKMP
Buy
Car rental group earnings to inflect on improved fundamentals, says MKM Partners
MKM Partners analyst Christopher Agnew raised his price target on Avis Budget Group (CAR) to $49 from $39 and Hertz Global (HTZ) to $36 from $22, maintaining a Buy rating on both stocks. Agnew says the earnings momentum for the group is at an upward inflection point thanks to sustained improvement in core fundamentals, as net pricing is turning positive. Agnew also notes other catalysts for these stocks, including overly high 40-50% short interest and cost reductions driven by "connected-cars" technology improvements.
10/06/17
DBAB
10/06/17
NO CHANGE
Target $49
DBAB
Buy
Deutsche Bank raises price targets in Rental Car space
Deutsche Bank analyst Chris Woronka raised his price target for Buy-rated Avis Budget Group (CAR) to $49 from $44 and for Hold-rated Hertz Global Holdings (HTZ) to $18 from $14. Both companies' third quarters were tracking favorably on both demand and pricing in the U.S. even before the hurricanes, Woronka tells investors in a research note. He believes the storms are likely to have a larger impact on demand in Q4 but a larger positive impact on residual values in Q3. The analyst raised his estimates "above consensus across the board" for both companies.
11/08/17
JPMS
11/08/17
NO CHANGE
Target $47
JPMS
Overweight
Avis Budget selloff on Q3 miss overdone, says JPMorgan
JPMorgan analyst Samik Chatterjee views the selloff in Avis Budget following the Q3 miss as overdone. The analyst believes the company's drivers of profitability remain favorable. He keeps an Overweight rating on the shares while lowering his price target to $47 from $50.
EMR Emerson
$61.48

-1.04 (-1.66%)

10/17/17
10/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Buy from Neutral at Mizuho with analyst Thomas Shrader saying he likes what he sees at Biogen again. 2. Prudential (PRU) upgraded to Buy from Neutral at Citi with analyst Suneet Kamath saying Prudential's current valuation does not give the company enough credit for the quality of its business mix. 3. Chevron (CVX) upgraded to Outperform from Neutral at Macquarie with analyst Iain Reid saying cost reduction efforts and new production volumes driving outstanding free cash generation, which should cover capex and the dividend at an oil price below $40/bbl from 2018 onward. 4. Energy Transfer Equity (ETE) upgraded to Buy from Neutral at Goldman Sachs with analyst Theodore Durbin saying he expects Energy Transfer Equity's above average distribution growth to be driven by an improving free cash flow profile. 5. Emerson (EMR) was upgraded to Outperform from Market Perform at Cowen and to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/17
WELS
11/08/17
NO CHANGE
Target $65
WELS
Market Perform
Emerson price target raised to $65 from $60 at Wells Fargo
Wells Fargo analyst Rich Kwas raised his price target for Emerson (EMR) to $65 from $60, saying that the Rockwell Automation (ROK) offer is still on the table and a resolution should come sometime in calendar Q1. The analyst reiterates a Market Perform rating on the shares.
11/01/17
WBLR
11/01/17
NO CHANGE
WBLR
Market Perform
Emerson 'highly unlikely' to be successful in buying Rockwell
William Blair analyst Nicholas Heymann finds it "highly unlikely" that Emerson Electric (EMR) can succeed in acquiring Rockwell Automation (ROK). Rockwell's "exceptional" record for shareholder value creation and "best-in-class" return on invested capital position it to reject "all but the most uneconomic acquisition offers," Heymann tells investors in a research note. The analyst has a Market Perform rating on both stocks.
10/31/17
WELS
10/31/17
NO CHANGE
WELS
Wells understands why Rockwell's board would seek higher multiple than B&R
Noting that ABB (ABB) agreed to buy industrial automation company Bernecker & Rainer at a multiple of roughly 21x EBITDA, Wells Fargo analyst Richard Kwas says he can understand why B&R rival Rockwell Automation's (ROK) board would reject a similar multiple from Emerson (EMR) considering B&R had a considerably lower EBIT margin than Rockwell. While Kwas views Rockwell as a unique asset and a good strategic fit for Emerson, he adds that total synergies would have to be "significant" to make a transaction work.
CCJ Cameco
$9.34

0.32 (3.55%)

10/03/17
SCOT
10/03/17
DOWNGRADE
SCOT
Underperform
Cameco downgraded to Underperform from Sector Perform at Scotiabank
07/18/17
07/18/17
DOWNGRADE

Underperform
Cameco downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst Robert Reynolds downgraded Cameco to Underperform from Neutral as his cataloguing of nuclear power plants drives his forecast for uranium demand below current industry expectations. The analyst reduced his longer-term price to $40/lb based on the 90th percentile of the cost curve, from a prior forecast for $60/lb based on an incentive price. Reynolds also lowered his price target on the shares to C$10 from C$13.50.
07/17/17
FBCO
07/17/17
DOWNGRADE
FBCO
Underperform
Cameco downgraded to Underperform from Neutral at Credit Suisse
06/30/17
BOFA
06/30/17
DOWNGRADE
BOFA
Underperform
Cameco downgraded to Underperform from Neutral at BofA/Merrill
AFSI AmTrust
$10.90

-1.36 (-11.09%)

02/28/17
JMPS
02/28/17
NO CHANGE
JMPS
AmTrust shares have reached 'highly attractive' entry point, says JMP Securities
JMP Securities analyst Matthew Carletti says that AmTrust reported "messy" Q4 results. However, the analyst thinks that the 19% decline in the stock was overdone and creates "a highly attractive" entry point. He says that the company's reserve charge is "quite manageable," while the material weakness in financial controls was "mostly" caused by "growing pains" that reflect the change to an auditor with higher standards. He cut his price target on the stock to $31 from $35 but keeps an Outperform rating.
04/12/17
RHCO
04/12/17
NO CHANGE
RHCO
Allegations against AmTrust 'unfounded,' says SunTrust
After an article in the Wall Street Journal reported an alleged probe in 2014 by the SEC regarding AmTrust's accounting for losses and reserves, SunTrust analyst Mark Hughes says that the allegations were made by a whistleblower working with a short selling group in 2014 and that the allegations did not yield any results at that time. Consequently, the analyst believes that the allegations are "unfounded." He keeps a $28 price target and a Buy rating on the shares.
10/24/17
10/24/17
DOWNGRADE
Target $14

Neutral
AmTrust downgraded to Neutral from Buy at FBR Capital
FBR Capital analyst Randy Binner downgraded AmTrust Financial Services to Neutral and cut his price target for the shares to $14 from $16. The analyst sees book value growth over the next year as unlikely due to reserve development challenges.
05/02/17
KBWI
05/02/17
DOWNGRADE
KBWI
Market Perform
AmTrust reinstated with a Market Perform from Outperform at Keefe Bruyette
DGX Quest Diagnostics
$93.02

-0.13 (-0.14%)

10/12/17
WELS
10/12/17
UPGRADE
Target $175
WELS
Outperform
LabCorp resumed with an Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of LabCorp and upgraded the shares to Outperform with a $175 price target. The analyst sees LabCorp outperforming Quest Diagnostics (DGX) due to its "slightly" higher revenue growth profile and diversification as well as more attractive valuation.
10/12/17
WELS
10/12/17
INITIATION
Target $88
WELS
Market Perform
Quest Diagnostics resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of Quest Diagnostics with a Market Perform rating and $88 price target. The rating is unchanged from his firm's prior coverage.
10/17/17
CHLM
10/17/17
NO CHANGE
Target $100
CHLM
Hold
Quest Diagnostics price target lowered to $100 from $110 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Quest Diagnostics to $100 from $110 to account for hurricane-related disruption in Florida, Texas, and Puerto Rico based on its disclosure in late September. The analyst views the weather-related impact as a one-time event. He reiterates a Hold rating on the shares.
10/10/17
10/10/17
DOWNGRADE
Target $113

Buy
Quest Diagnostics removed from Conviction Buy List at Goldman Sachs
As previously reported, Goldman removed Quest Diagnostics from the Conviction Buy List and lowered its price target to $113 from $121. Analyst Isaac Ro thinks share gains associated with PAMA reimbursement cuts could take time to manifest as competitors debate long-term strategies. The analyst maintains a Buy rating on Quest given its a pure-play on lab testing, margin expansion opportunities, and shareholder friendly capital deployment.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$315.05

2.55 (0.82%)

10:21
11/18/17
11/18
10:21
11/18/17
10:21
Periodicals
Tesla new super car to cost $200,000, Recode says »

Alongside its new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 16

    Jan

GT

Goodyear Tire

$29.94

0.63 (2.15%)

10:17
11/18/17
11/18
10:17
11/18/17
10:17
Hot Stocks
Goodyear Tire, NASCAR extend relationship »

NASCAR and Goodyear Tire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Jan

  • 16

    Jan

HMC

Honda

$32.62

0.02 (0.06%)

10:05
11/18/17
11/18
10:05
11/18/17
10:05
Periodicals
Honda recalls 900,000 minivans on tip forward seats, Reuters says »

Honda Motor is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$88.43

-0.82 (-0.92%)

09:48
11/18/17
11/18
09:48
11/18/17
09:48
Periodicals
Activist investors Nelson Peltz still in P&G picture, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

, GE

General Electric

$18.21

-0.04 (-0.22%)

09:39
11/18/17
11/18
09:39
11/18/17
09:39
Periodicals
Buy Baker Hughes, Barron's says »

While it is "not…

BHGE

Baker Hughes

$30.91

0.76 (2.52%)

GE

General Electric

$18.21

-0.04 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

CSCO

Cisco

$35.90

0.02 (0.06%)

09:19
11/18/17
11/18
09:19
11/18/17
09:19
Periodicals
More needed for Cisco to have 'groove back,' Barron's says »

While the Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

IBM

IBM

$148.97

-0.15 (-0.10%)

09:10
11/18/17
11/18
09:10
11/18/17
09:10
Periodicals
IBM could be next to fetch higher valuation, Barron's says »

Investors are warming to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$18.21

-0.04 (-0.22%)

09:05
11/18/17
11/18
09:05
11/18/17
09:05
Periodicals
Option play offer some help given GE dividend, depressed stock, Barron's says »

While wagering against…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

09:00
11/18/17
11/18
09:00
11/18/17
09:00
Periodicals
Risk remains after GE dividend cut, Barron's says »

While buying General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$88.72

0.71 (0.81%)

, T

AT&T

$34.51

-0.01 (-0.03%)

08:21
11/18/17
11/18
08:21
11/18/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

TWX

Time Warner

$88.72

0.71 (0.81%)

T

AT&T

$34.51

-0.01 (-0.03%)

NYT

New York Times

$17.65

0.05 (0.28%)

TEX

Terex

$44.82

0.8 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

TPIC

TPI Composites

$19.06

-0.97 (-4.84%)

07:25
11/18/17
11/18
07:25
11/18/17
07:25
Conference/Events
TPI Composites to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SYNA

Synaptics

$38.21

0.57 (1.51%)

04:55
11/18/17
11/18
04:55
11/18/17
04:55
Conference/Events
Synaptics management to meet with KeyBanc »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.